MindWalk Holdings Corp.

NasdaqCM:HYFT Stock Report

Market Cap: US$63.1m

MindWalk Holdings Balance Sheet Health

Financial Health criteria checks 4/6

MindWalk Holdings has a total shareholder equity of CA$11.7M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$21.4M and CA$9.6M respectively.

Key information

0%

Debt to equity ratio

CA$0

Debt

Interest coverage ration/a
CashCA$11.35m
EquityCA$11.75m
Total liabilitiesCA$9.63m
Total assetsCA$21.38m

Recent financial health updates

Analysis Article Apr 22

Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Narrative Update Jul 30

Re-Evaluating MindWalk Holdings: Cash Runway Realities and Fair Value Calculations

In our initial investment thesis, we framed MindWalk as an asymmetric TechBio play with an $8.27 USD fair value target. Our core thesis rested on the company’s pivot from a capital-intensive wet-lab Contract Research Organization (CRO) to a high-margin, scalable software-as-a-service (SaaS) platform powered by its proprietary BioNative HYFT technology.
New Narrative Jun 18

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

MindWalk Holdings Corp. (NASDAQ: HYFT) presents a classic case of market mispricing driven by a transitional lag.
Analysis Article Jan 08

MindWalk Holdings Corp.'s (NASDAQ:HYFT) P/S Is Still On The Mark Following 38% Share Price Bounce

MindWalk Holdings Corp. ( NASDAQ:HYFT ) shareholders have had their patience rewarded with a 38% share price jump in...
Seeking Alpha Oct 17

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

Summary MindWalk Holdings (HYFT) has pivoted to an asset-light, AI-driven techbio platform, leveraging its HYFT and LensAI technologies for in silico drug discovery. LensAI's early successes include a dual-action GLP-1 agonist and a universal dengue vaccine candidate, highlighting HYFT's practical potential and commercial promise. HYFT reported record quarterly sales, improved margins, and a strengthened balance sheet post-divestiture. At an $75 million valuation, HYFT remains undervalued relative to  other techbio players; I assign a Buy rating based on its platform, partnerships, and growth outlook. Read the full article on Seeking Alpha
Analysis Article Jun 24

Even With A 72% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely

Despite an already strong run, ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shares have been powering on, with a gain...
User avatar
New Narrative May 05

AI Driven Partnerships Will Open New Biotech Opportunities

Strategic partnerships and tech collaborations are anticipated to boost revenue streams, improve net margins, and enhance operational efficiency.
Analysis Article May 04

ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Shares Leap 28% Yet They're Still Not Telling The Full Story

ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shareholders would be excited to see that the share price has had a great...
Analysis Article Apr 22

Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jan 17

Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely

ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shares have had a really impressive month, gaining 30% after a shaky...
Analysis Article Nov 24

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shareholders that were waiting for something to happen have been dealt a...
Seeking Alpha Sep 14

ImmunoPrecise Antibodies reports FQ1 results

ImmunoPrecise Antibodies press release (NASDAQ:IPA): FQ1 Revenue of C$4.7M (+2.2% Y/Y). As of July 31, 2022, the company held cash of C$19.2M as compared to C$30.0M as of April 30, 2022, and had working capital of C$21.7M. The company’s internal forecast indicates the cash on hand will sustain its existing operations for at least 12 months.

Financial Position Analysis

Short Term Liabilities: HYFT's short term assets (CA$16.2M) exceed its short term liabilities (CA$5.8M).

Long Term Liabilities: HYFT's short term assets (CA$16.2M) exceed its long term liabilities (CA$3.8M).


Debt to Equity History and Analysis

Debt Level: HYFT is debt free.

Reducing Debt: HYFT has no debt compared to 5 years ago when its debt to equity ratio was 2.7%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HYFT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HYFT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.3% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/31 07:41
End of Day Share Price 2026/07/31 00:00
Earnings2026/04/30
Annual Earnings2026/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MindWalk Holdings Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthATB Cormark Historical (Cormark Securities)
Robert WassermanBenchmark Company
Swayampakula RamakanthH.C. Wainwright & Co.